In high prevalence regions, current recommendations are to screen individuals with blood CD4+ T cell counts less than 200 cells/μl for serum cryptococcal antigen (CrAg) and then preemptively treat those who test positive for presumed cryptococcosis. This evidence concerns the gene CD4 and cryptococcosis.